Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study | Zendy

Yuping Li | Zendy; Keqing Shi | Zendy; Qi Feng | Zendy; Zhijie Yu | Zendy; Chengshui Chen | Zendy; Jingye Pan | Zendy; Gaojun Wu | Zendy; Yanfang Chen | Zendy; Ji Li | Zendy; Yongping Chen | Zendy; Tieli Zhou | Zendy; Xiaokun Li | Zendy; Jinglin Xia | Zendy

Open Access

Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study

Author(s) -

Yuping Li,

Keqing Shi,

Qi Feng,

Zhijie Yu,

Chengshui Chen,

Jingye Pan,

Gaojun Wu,

Yanfang Chen,

Ji Li,

Yongping Chen,

Tieli Zhou,

Xiaokun Li,

Jinglin Xia

Publication year - 2020

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2020.12.023

Subject(s) - thalidomide , medicine , dexamethasone , glucocorticoid , regimen , cytokine , gastroenterology , surgery , multiple myeloma

The aim was to evaluate the safety and effectiveness of thalidomide, an immunomodulatory agent, in combination with glucocorticoid, for the treatment of COVID-19 patients with life-threatening symptoms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog